Evidence map›Paper›PMID 32787947›Full record

ArticleBMC gastroenterology2020

Validation of a new prognostic model to predict short and medium-term survival in patients with liver cirrhosis.

Tomasz Dziodzio, Robert Öllinger, Wenzel Schöning, Antonia Rothkäppel, Radoslav Nikolov, Andrzej Juraszek, Paul V Ritschl, Martin Stockmann, Johann Pratschke, Maximilian Jara

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Tomasz DziodzioCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Surgery - Campus Charité Mitte / Campus Virchow-Klinikum, Augustenburger Platz 1 |, 13353, Berlin, Germany. tomasz.dziodzio@charite.de.ORCID http://orcid.org/0000-0002-3337-4573
Robert ÖllingerCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Surgery - Campus Charité Mitte / Campus Virchow-Klinikum, Augustenburger Platz 1 |, 13353, Berlin, Germany.
Wenzel SchöningCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Surgery - Campus Charité Mitte / Campus Virchow-Klinikum, Augustenburger Platz 1 |, 13353, Berlin, Germany.
Antonia RothkäppelCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Surgery - Campus Charité Mitte / Campus Virchow-Klinikum, Augustenburger Platz 1 |, 13353, Berlin, Germany.
Radoslav NikolovCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Surgery - Campus Charité Mitte / Campus Virchow-Klinikum, Augustenburger Platz 1 |, 13353, Berlin, Germany.
Andrzej JuraszekCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Surgery - Campus Charité Mitte / Campus Virchow-Klinikum, Augustenburger Platz 1 |, 13353, Berlin, Germany.
Paul V RitschlCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Surgery - Campus Charité Mitte / Campus Virchow-Klinikum, Augustenburger Platz 1 |, 13353, Berlin, Germany.
Martin StockmannCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Surgery - Campus Charité Mitte / Campus Virchow-Klinikum, Augustenburger Platz 1 |, 13353, Berlin, Germany.
Johann PratschkeCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Surgery - Campus Charité Mitte / Campus Virchow-Klinikum, Augustenburger Platz 1 |, 13353, Berlin, Germany.
Maximilian JaraCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Surgery - Campus Charité Mitte / Campus Virchow-Klinikum, Augustenburger Platz 1 |, 13353, Berlin, Germany.
Humboldt-Universität zu Berlin · DE

Funding

FP7 Ideas: European Research Council 287596
6 · The paper itself

Abstract

backgroundMELD score and MELD score derivates are used to objectify and grade the risk of liver-related death in patients with liver cirrhosis. We recently proposed a new predictive model that combines serum creatinine levels and maximum liver function capacity (LiMAx®), namely the CreLiMAx risk score. In this validation study we have aimed to reproduce its diagnostic accuracy in patients with end-stage liver disease.

methodsLiver function of 113 patients with liver cirrhosis was prospectively investigated. Primary end-point of the study was liver-related death within 12 months of follow-up.

resultsAlcoholic liver disease was the main cause of liver disease (n = 51; 45%). Within 12 months of follow-up 11 patients (9.7%) underwent liver transplantation and 17 (15.1%) died (13 deaths were related to liver disease, two not). Measures of diagnostic accuracy were comparable for MELD, MELD-Na and the CreLiMAx risk score as to power in predicting short and medium-term mortality risk in the overall cohort: AUROCS for liver related risk of death were for MELD [6 months 0.89 (95% CI 0.80-0.98) p < 0.001; 12 months 0.89 (95% CI 0.81-0.96) p < 0.001]; MELD-Na [6 months 0.93 (95% CI 0.85-1.00) p < 0.001 and 12 months 0.89 (95% CI 0.80-0.98) p < 0.001]; CPS 6 months 0.91 (95% CI 0.85-0.97) p < 0.01 and 12 months 0.88 (95% CI 0.80-0.96) p < 0.001] and CreLiMAx score [6 months 0.80 (95% CI 0.67-0.96) p < 0.01 and 12 months 0.79 (95% CI 0.64-0.94) p = 0.001]. In a subgroup analysis of patients with Child-Pugh Class B cirrhosis, the CreLiMAx risk score remained the only parameter significantly differing in non-survivors and survivors. Furthermore, in these patients the proposed score had a good predictive performance.

conclusionThe CreLiMAx risk score appears to be a competitive and valid tool for estimating not only short- but also medium-term survival of patients with end-stage liver disease. Particularly in patients with Child-Pugh Class B cirrhosis the new score showed a good ability to identify patients not at risk of death.

Indexed as

Liver CirrhosisLiver TransplantationHumansLiver Function TestsPrognosisRetrospective StudiesROC CurveSeverity of Illness IndexEnd-stage liver diseaseLiMAx®MELDMortality riskPrognosisSurvivalSurvival scores

Identifiers

PMID32787947
PMCPMC7425128
OpenAlexW3048722792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.